Novo Nordisk Foundation: Sanders’ criticism unfounded

Novo Nordisk Foundation’s CEO, Mads Krogsgaard, contends that U.S. Senator Bernie Sanders’ criticism of the drug pricing for Ozempic and Wegovy in the USA is misplaced. In TV 2 News’ Business Class magazine, Krogsgaard argued that Sanders overlooks how the American healthcare system’s intermediaries significantly mark up drug prices, capturing on average three-quarters of the list price. This response comes after Sanders published an opinion piece asserting that Denmark’s population should encourage Novo Nordisk to reduce prices for these drugs in the U.S., pointing out that many Americans can’t afford these medications and claiming that the high prices could harm the nation’s healthcare system.